Asymchem Laboratories (Tianjin) Past Earnings Performance
Past criteria checks 2/6
Asymchem Laboratories (Tianjin) has been growing earnings at an average annual rate of 25.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 24.2% per year. Asymchem Laboratories (Tianjin)'s return on equity is 4.5%, and it has net margins of 13.8%.
Key information
25.9%
Earnings growth rate
23.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 24.2% |
| Return on equity | 4.5% |
| Net Margin | 13.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Troubles May Signal Larger Issues for Asymchem Laboratories (Tianjin) (SZSE:002821) Shareholders
Nov 05
Estimating The Intrinsic Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Oct 15Investors Still Aren't Entirely Convinced By Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Earnings Despite 25% Price Jump
Sep 28Is There An Opportunity With Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) 49% Undervaluation?
Jul 16Asymchem Laboratories (Tianjin) (SZSE:002821) Is Paying Out A Dividend Of CN¥1.80
Jun 27Benign Growth For Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Underpins Its Share Price
Jun 26Does Asymchem Laboratories (Tianjin) (SZSE:002821) Have A Healthy Balance Sheet?
May 22Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Just Missed Earnings: Here's What Analysts Think Will Happen Next
Apr 03Downgrade: Here's How Analysts See Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Performing In The Near Term
Apr 02A Look At The Fair Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Mar 26Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 04Revenue & Expenses Breakdown
How Asymchem Laboratories (Tianjin) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,571 | 769 | 994 | 679 |
| 30 Jun 24 | 5,901 | 1,082 | 1,016 | 713 |
| 31 Mar 24 | 6,976 | 1,920 | 1,019 | 715 |
| 31 Dec 23 | 7,825 | 2,269 | 991 | 708 |
| 30 Sep 23 | 8,801 | 2,791 | 1,060 | 780 |
| 30 Jun 23 | 9,836 | 3,248 | 975 | 769 |
| 31 Mar 23 | 10,445 | 3,433 | 976 | 740 |
| 01 Jan 23 | 10,255 | 3,302 | 980 | 709 |
| 30 Sep 22 | 9,508 | 3,094 | 853 | 572 |
| 30 Jun 22 | 7,918 | 2,382 | 801 | 487 |
| 31 Mar 22 | 5,915 | 1,413 | 672 | 435 |
| 31 Dec 21 | 4,632 | 1,068 | 594 | 387 |
| 30 Sep 21 | 3,977 | 908 | 522 | 346 |
| 30 Jun 21 | 3,626 | 830 | 471 | 314 |
| 31 Mar 21 | 3,438 | 766 | 468 | 288 |
| 31 Dec 20 | 3,137 | 719 | 427 | 259 |
| 30 Sep 20 | 2,800 | 694 | 392 | 228 |
| 30 Jun 20 | 2,633 | 640 | 380 | 223 |
| 31 Mar 20 | 2,459 | 570 | 360 | 210 |
| 31 Dec 19 | 2,460 | 554 | 360 | 193 |
| 30 Sep 19 | 2,372 | 534 | 347 | 188 |
| 30 Jun 19 | 2,170 | 501 | 343 | 179 |
| 31 Mar 19 | 1,948 | 457 | 308 | 161 |
| 31 Dec 18 | 1,835 | 428 | 284 | 155 |
| 30 Sep 18 | 1,732 | 401 | 246 | 130 |
| 30 Jun 18 | 1,629 | 373 | 170 | 152 |
| 31 Mar 18 | 1,497 | 356 | 184 | 128 |
| 31 Dec 17 | 1,423 | 341 | 201 | 97 |
| 30 Sep 17 | 1,213 | 265 | 237 | 69 |
| 30 Jun 17 | 1,184 | 289 | 285 | 0 |
| 31 Mar 17 | 1,207 | 269 | 276 | 0 |
| 31 Dec 16 | 1,103 | 253 | 257 | 0 |
| 30 Sep 16 | 1,097 | 260 | 220 | 0 |
| 31 Dec 15 | 831 | 154 | 203 | 0 |
| 31 Dec 14 | 716 | 102 | 173 | 0 |
| 31 Dec 13 | 543 | 75 | 136 | 0 |
Quality Earnings: 002821 has high quality earnings.
Growing Profit Margin: 002821's current net profit margins (13.8%) are lower than last year (31.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002821's earnings have grown significantly by 25.9% per year over the past 5 years.
Accelerating Growth: 002821's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002821 had negative earnings growth (-72.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 002821's Return on Equity (4.5%) is considered low.